Top Indian drugmaker Sun Pharma's Q3 profit beats estimates on strong local sales
By Kashish Tandon and Rishika Sadam HYDERABAD/BENGALURU (Reuters) -Sun Pharmaceutical, India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided by strong sales in the domestic market.
Sun Pharma Q3 Results: Net profit up 15%; revenue at Rs 13,675 crore
Results: Sun Pharmaceutical Industries on Friday said its consolidated net profit increased 15 per cent on-year to Rs 2,903 crore in the December quarter, riding on robust sales across geographies.
Sun Pharma's Profits Shine Amid Global Sales Surge
Sun Pharmaceutical Industries reported a 15% rise in net profit for the December quarter, driven by strong global sales. The company's revenue reached Rs 13,675 crore. An interim dividend of Rs 10.5 per share for FY25 was declared.
Sun Pharma shares rise nearly 3% after Q3 profit beats estimates. What should investors do?
Sun Pharma reported a 15% YoY rise in Q3FY25 profit to Rs 2,903 crore, surpassing estimates. Revenue grew 10% to Rs 13,675.5 crore, driven by domestic and emerging markets. API sales rose 22%, while formulation sales in the US slightly declined.
Sun Pharma Q3 PAT rises 15% to ₹2,903 crore
Sun Pharmaceutical Industries Ltd. reported consolidated net profit rose 15% to ₹2,903 crore for the third quarter ended December 31, 2024 from ₹2,524 crore a year earlier. Gross sales during the quarter grew 10.5% year on year (YoY) to ₹13,437 crore).
India's top drugmaker Sun Pharma's Q3 profit beats estimates on strong local sales
Sun Pharmaceutical , India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided by strong sales in the domestic market.
Sun Pharma net profit jumps 15% to Rs 2,903 crore in Q3FY25
Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue grew 10.5%, while EBITDA surged 15.3% with improved margins. The company faces ongoing legal proceedings in the U.
Sun Pharma Q3 Results: PAT advances 15% YoY to Rs 2,903 crore, beats estimates
Results: The company has also declared an interim dividend of Rs 10.5 per share for the financial year 2024-25.
cnbctv181d
Sun Pharma analysts see stock testing ₹2,400 levels; Should you buy or sell?
Out of the 41 analysts that have coverage on Sun Pharma, 30 of them have a 'Buy' rating on the stock. Seven of them have a ...
Sun Pharma Consolidated December 2024 Net Sales at Rs 13,675.46 crore, up 10.46% Y-o-Y
Net Sales at Rs 13,675.46 crore in December 2024 up 10.46% from Rs. 12,380.70 crore in December 2023. Quarterly Net Profit at ...
Sun Pharma Share Price Highlights: Sun Pharma Stock Price History
Stay updated with the Sun Pharma Stock Liveblog, your one-stop destination for real-time information and analysis of a ...
Sun Pharmaceutical Industries falls Friday, underperforms market
Sun Pharmaceutical Industries Ltd. closed 11.08% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.
Sun Pharma Standalone December 2024 Net Sales at Rs 6,191.81 crore, up 22.04% Y-o-Y
Net Sales at Rs 6,191.81 crore in December 2024 up 22.04% from Rs. 5,073.75 crore in December 2023. Quarterly Net Profit at ...
Stocks in news on Budget day: ITC, Sun Pharma, Vishal Mega Mart, Infosys, Hero MotoCorp, HUL, RVNL, IRCTC
So, watch out for ITC, Sun Pharma, Vishal Mega Mart, Infosys, Hero MotoCorp, HUL, RVNL, IRCTC and a slew of other stocks that ...